Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia - PubMed (original) (raw)

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia

Sanne Lugthart et al. Cancer Cell. 2005 Apr.

Free article

Abstract

Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibiting crossresistance to prednisolone, vincristine, asparaginase, and daunorubicin. We also identified a distinct phenotype of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel phenotype. The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS).

PubMed Disclaimer

Similar articles

• Building better therapy for children with acute lymphoblastic leukemia.
  Carroll WL, Raetz EA. Carroll WL, et al. Cancer Cell. 2005 Apr;7(4):289-91. doi: 10.1016/j.ccr.2005.04.003. Cancer Cell. 2005. PMID: 15837616
• Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
  Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R. Stams WA, et al. Clin Cancer Res. 2005 Apr 15;11(8):2974-80. doi: 10.1158/1078-0432.CCR-04-1829. Clin Cancer Res. 2005. PMID: 15837750
• Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
  Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Holleman A, et al. N Engl J Med. 2004 Aug 5;351(6):533-42. doi: 10.1056/NEJMoa033513. N Engl J Med. 2004. PMID: 15295046
• Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
  Ronghe M, Burke GA, Lowis SP, Estlin EJ. Ronghe M, et al. Cancer Treat Rev. 2001 Dec;27(6):327-37. doi: 10.1053/ctrv.2001.0243. Cancer Treat Rev. 2001. PMID: 11908926 Review.
• [Treatment of acute leukemias].
  Brilliant MD. Brilliant MD. Ter Arkh. 1973 Sep;45(9):72-85. Ter Arkh. 1973. PMID: 4585646 Review. Russian. No abstract available.

Cited by

• Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
  Rose-James A, Shiji R, Kusumakumary P, Nair M, George SK, Sreelekha TT. Rose-James A, et al. Med Oncol. 2016 Sep;33(9):98. doi: 10.1007/s12032-016-0809-x. Epub 2016 Jul 23. Med Oncol. 2016. PMID: 27449773
• A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm.
  Evans WE, Crews KR, Pui CH. Evans WE, et al. Clin Pharmacol Ther. 2013 Aug;94(2):224-9. doi: 10.1038/clpt.2013.9. Epub 2013 Jan 17. Clin Pharmacol Ther. 2013. PMID: 23462885 Free PMC article. Review.
• A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
  Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N. Sugimoto K, et al. Cancer Sci. 2015 Nov;106(11):1534-43. doi: 10.1111/cas.12807. Epub 2015 Oct 16. Cancer Sci. 2015. PMID: 26331698 Free PMC article.
• TNFR2 is required for RIP1-dependent cell death in human leukemia.
  Aguadé-Gorgorió J, McComb S, Eckert C, Guinot A, Marovca B, Mezzatesta C, Jenni S, Abduli L, Schrappe M, Dobay MP, Stanulla M, von Stackelberg A, Cario G, Bourquin JP, Bornhauser BC. Aguadé-Gorgorió J, et al. Blood Adv. 2020 Oct 13;4(19):4823-4833. doi: 10.1182/bloodadvances.2019000796. Blood Adv. 2020. PMID: 33027529 Free PMC article.
• The pharmacogenetics research network: from SNP discovery to clinical drug response.
  Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network. Giacomini KM, et al. Clin Pharmacol Ther. 2007 Mar;81(3):328-45. doi: 10.1038/sj.clpt.6100087. Clin Pharmacol Ther. 2007. PMID: 17339863 Free PMC article. Review.

Publication types

MeSH terms

Substances

Grants and funding

• P30 CA21765/CA/NCI NIH HHS/United States
• R01 CA51001/CA/NCI NIH HHS/United States
• R01 CA78224/CA/NCI NIH HHS/United States
• R37 CA36401/CA/NCI NIH HHS/United States
• U01 GM61374/GM/NIGMS NIH HHS/United States
• U01 GM61393/GM/NIGMS NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases